| Dr Anas Hakam Safadi, MD | |
|
1500 S Lake Park Ave, Hobart, IN 46342-6638 | |
| (219) 947-6017 | |
| (219) 947-6018 |
| Full Name | Dr Anas Hakam Safadi |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 20 Years |
| Location | 1500 S Lake Park Ave, Hobart, Indiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1457452484 | NPI | - | NPPES |
| 01060952A | Other | IN | LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 01060952A (Indiana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Mary Medical Center Inc | Hobart, IN | Hospital |
| Community Hospital | Munster, IN | Hospital |
| Methodist Hospitals Inc | Gary, IN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Community Care Network Inc | 3678737012 | 360 |
News Archive
Publishing in the current issue of The Journal of Biological Chemistry (Vol. 286, No 43), researchers at Moffitt Cancer Center in Tampa, Fla., have discovered additional mechanisms of "Akt" activation and suggest a component of that activation mechanism - inhibitor of nuclear factor kappa-B kinase subunit epsilon (IKBKE) - could be targeted as a therapeutic intervention for treating cancer.
Genzyme Corporation announced today that it has received a June 17, 2010 PDUFA date from the FDA for its Biologics License Application for Lumizyme™ (alglucosidase alfa) seeking approval for the therapy produced at the 4000 L scale.
Some studies have shown that a relationship of hepatitis C (HCV) infection with type II mixed cryoglobulinemia exists.
The New York Times' "India Ink" blog examines how "a growing number of 'affordable health care' entrepreneurs are focused on developing new solutions for the rural and remote parts of the country."
› Verified 7 days ago
| Entity Name | Cardiodiagnostics, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144279241 PECOS PAC ID: 6406755503 Enrollment ID: O20040107000901 |
News Archive
Publishing in the current issue of The Journal of Biological Chemistry (Vol. 286, No 43), researchers at Moffitt Cancer Center in Tampa, Fla., have discovered additional mechanisms of "Akt" activation and suggest a component of that activation mechanism - inhibitor of nuclear factor kappa-B kinase subunit epsilon (IKBKE) - could be targeted as a therapeutic intervention for treating cancer.
Genzyme Corporation announced today that it has received a June 17, 2010 PDUFA date from the FDA for its Biologics License Application for Lumizyme™ (alglucosidase alfa) seeking approval for the therapy produced at the 4000 L scale.
Some studies have shown that a relationship of hepatitis C (HCV) infection with type II mixed cryoglobulinemia exists.
The New York Times' "India Ink" blog examines how "a growing number of 'affordable health care' entrepreneurs are focused on developing new solutions for the rural and remote parts of the country."
› Verified 7 days ago
| Entity Name | Methodist Hospitals Cardiographics, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609825686 PECOS PAC ID: 0749244499 Enrollment ID: O20041112001053 |
News Archive
Publishing in the current issue of The Journal of Biological Chemistry (Vol. 286, No 43), researchers at Moffitt Cancer Center in Tampa, Fla., have discovered additional mechanisms of "Akt" activation and suggest a component of that activation mechanism - inhibitor of nuclear factor kappa-B kinase subunit epsilon (IKBKE) - could be targeted as a therapeutic intervention for treating cancer.
Genzyme Corporation announced today that it has received a June 17, 2010 PDUFA date from the FDA for its Biologics License Application for Lumizyme™ (alglucosidase alfa) seeking approval for the therapy produced at the 4000 L scale.
Some studies have shown that a relationship of hepatitis C (HCV) infection with type II mixed cryoglobulinemia exists.
The New York Times' "India Ink" blog examines how "a growing number of 'affordable health care' entrepreneurs are focused on developing new solutions for the rural and remote parts of the country."
› Verified 7 days ago
| Entity Name | Community Care Network Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457610487 PECOS PAC ID: 3678737012 Enrollment ID: O20120614000331 |
News Archive
Publishing in the current issue of The Journal of Biological Chemistry (Vol. 286, No 43), researchers at Moffitt Cancer Center in Tampa, Fla., have discovered additional mechanisms of "Akt" activation and suggest a component of that activation mechanism - inhibitor of nuclear factor kappa-B kinase subunit epsilon (IKBKE) - could be targeted as a therapeutic intervention for treating cancer.
Genzyme Corporation announced today that it has received a June 17, 2010 PDUFA date from the FDA for its Biologics License Application for Lumizyme™ (alglucosidase alfa) seeking approval for the therapy produced at the 4000 L scale.
Some studies have shown that a relationship of hepatitis C (HCV) infection with type II mixed cryoglobulinemia exists.
The New York Times' "India Ink" blog examines how "a growing number of 'affordable health care' entrepreneurs are focused on developing new solutions for the rural and remote parts of the country."
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Anas Hakam Safadi, MD 1500 S Lake Park Ave, Hobart, IN 46342-6638 Ph: (219) 947-6017 | Dr Anas Hakam Safadi, MD 1500 S Lake Park Ave, Hobart, IN 46342-6638 Ph: (219) 947-6017 |
News Archive
Publishing in the current issue of The Journal of Biological Chemistry (Vol. 286, No 43), researchers at Moffitt Cancer Center in Tampa, Fla., have discovered additional mechanisms of "Akt" activation and suggest a component of that activation mechanism - inhibitor of nuclear factor kappa-B kinase subunit epsilon (IKBKE) - could be targeted as a therapeutic intervention for treating cancer.
Genzyme Corporation announced today that it has received a June 17, 2010 PDUFA date from the FDA for its Biologics License Application for Lumizyme™ (alglucosidase alfa) seeking approval for the therapy produced at the 4000 L scale.
Some studies have shown that a relationship of hepatitis C (HCV) infection with type II mixed cryoglobulinemia exists.
The New York Times' "India Ink" blog examines how "a growing number of 'affordable health care' entrepreneurs are focused on developing new solutions for the rural and remote parts of the country."
› Verified 7 days ago
Maali Milhem, MBBS Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1354 S Lake Park Ave, Hobart, IN 46342 Phone: 219-945-5888 Fax: 219-945-5880 | |
Javairia Quraishi, MD Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 1500 S Lake Park Ave, Hobart, IN 46342 Phone: 219-945-4580 Fax: 219-945-4581 | |
Abdul Tamim Ward, DO Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 1500 S Lake Park Ave, Hobart, IN 46342 Phone: 055-121-9942 | |
Dr. May Y. Lee, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 7875 Grand Blvd, Pulmonary Specialists Of Northwest Indiana, Pc, Hobart, IN 46342 Phone: 219-942-9658 Fax: 219-947-1996 | |
Denise C Weaver, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1400 S Lake Park Ave Ste 304, Hobart, IN 46342 Phone: 219-947-6638 Fax: 219-703-6693 | |
Milton Stanley Gasparis, MD PHD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1352 S Lake Park Ave, Hobart, IN 46342 Phone: 219-942-7244 Fax: 219-942-0975 | |
Bantu Samridhi Chhangani, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1500 S Lake Park Ave, Hobart, IN 46342 Phone: 219-942-0551 |